Russell Investments Group
LCTX icon

Russell Investments Group’s Lineage Cell Therapeutics LCTX Stock Holding History

Russell Investments Group’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.3K Buy
+14,737
New +$20.4K ﹤0.01% 3815
2022
Q2 		– Sell
-6,964
Closed -$10K – 2935
2022
Q1 		$10K Hold
6,964
– – ﹤0.01% 2709
2021
Q4 		$17K Sell
6,964
-5,420
-44% -$12.7K ﹤0.01% 2958
2021
Q3 		$31K Sell
12,384
-3,402
-22% -$8.73K ﹤0.01% 2976
2021
Q2 		$44K Buy
+15,786
New +$40.8K ﹤0.01% 3138
2020
Q3 		– Sell
-761,830
Closed -$665K – 3223
2020
Q2 		$665K Buy
+761,830
New +$670K ﹤0.01% 2263
2018
Q3 		– Sell
-35,778
Closed -$65K – 2987
2018
Q2 		$65K Buy
35,778
+2,514
+8% +$5.06K ﹤0.01% 2787
2018
Q1 		$78K Sell
33,264
-13,830
-29% -$32.4K ﹤0.01% 2778
2017
Q4 		$92K Sell
47,094
-12,801
-21% -$28K ﹤0.01% 2793
2017
Q3 		$149K Sell
59,895
-62,932
-51% -$156K ﹤0.01% 2718
2017
Q2 		$339K Buy
122,827
+12,753
+12% +$35.6K ﹤0.01% 2552
2017
Q1 		$333K Buy
110,074
+83,009
+307% +$236K ﹤0.01% 2571
2016
Q4 		$86K Buy
+27,065
New +$83.1K ﹤0.01% 2907

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Russell Investments Group's LCTX Position: Q2 2026 in Review

Russell Investments Group opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 14,737 shares worth $19.3K. The stake represents ﹤0.01% of the portfolio and ranks #3815 among its holdings. This is a return to the name: Russell Investments Group previously reported a position in LCTX as recently as Q1 2022.

Russell Investments Group first reported a position in LCTX in Q4 2016 and has held it in 13 quarters since. The position peaked at $665K in Q2 2020. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Russell Investments Group held 14,737 shares of Lineage Cell Therapeutics worth $19.3K as of Q2 2026.
  • Lineage Cell Therapeutics was a new Russell Investments Group position in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3815 holding.
  • Russell Investments Group first reported a position in Lineage Cell Therapeutics in Q4 2016 and has held it in 13 quarters since.
  • Russell Investments Group's Lineage Cell Therapeutics position peaked at $665K in Q2 2020.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.